Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most…
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared…
Novo’s CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of…
Hundreds of lawsuits filed against some GLP-1 Makers over vision loss
Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned…
Novo cuts 13,000 jobs in a year – The Irish Times
Novo said on Monday it had cut its workforce by 13,000 in the past year as the maker…
The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?
Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule…
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments…
Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters
On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days…
Sun Pharma Requires High Court Approval for Semaglutide Tablet Launch Amid Patent Dispute, ETPharma
New Delhi: The Delhi High Court on Tuesday asked Sun Pharma Laboratories to take its prior approval before…
Amazon Is Bringing the Weight-Loss Drug Race to Medicare
This article first appeared on GuruFocus. Amazon.com Inc. (AMZN, Financials), the e-commerce and cloud-computing company, is expanding its…
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
Quick Read LLY raised 2026 guidance to $82B-$85B as Mounjaro and Zepbound surged, while NVO guided to an…
Hairdressers selling ‘Ozempic’: SA’s wild weight loss market
A recent high-profile court judgment halting a Pretoria pharmacy from selling GLP-1 drugs at scale has seemingly done…